Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.68, No.3, p.638–644,2021 |
||
| Title: Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients | ||
| Author: Lili Hu, Xintong Mao, Chao Gao, Yinhai Xu, Chenglin Li, Tao Wang, Dongmei Lv | ||
| Abstract: CDA 435C>T is reported as a functional SNP but there is no relevant research on the efficacy/hematological toxicity of gemcitabine-platinum treatment in Chinese non-small-cell lung cancer (NSCLC) patients. In this study, 63 patients who received radical resection (stage ⅠB or Ⅲ A) and 100 advanced NSCLC (stage IIIB or IV) patients have been collected, and all were treated with gemcitabine-platinum regimens from February of 2017 to February 2019. CDA 435C>T polymorphisms have been detected by PCR and direct sequencing. CT scan results and blood routine examinations have been collected to evaluate the efficacy and hematological toxicity. Then the relationships have been analyzed about CDA 435C>T. We found that T allele carriers have better therapy response (P < 0.05). Patients carrying CDA 435 C/T or T/T genotypes are statistically associated with a better efficacy (P < 0.05) but are more prone to leukopenia (P 0.05), in the case of 100 stage IIIB-IV patients, the CDA 435C/T and T/T have an increased risk (P < 0.05). Regarding the CDA 435C>T polymorphism in the Chinese population, in patients with the mutant T allele, gemcitabine is more effective, but they are more prone to suffering from hematological toxicity, especially the late-stage patients. |
||
| Keywords: NSCLC; gemcitabine; cytidine deaminase; silent mutation; toxicity | ||
| Published online: 16-Mar-2021 | ||
| Year: 2021, Volume: 68, Issue: 3 | Page From: 638, Page To: 644 | |
| doi:10.4149/neo_2021_201116N1229 |
||
|
|
 download file |
|